AU2015263013B2 - Fused triazole derivatives as phosphodiesterase 10A inhibitors - Google Patents
Fused triazole derivatives as phosphodiesterase 10A inhibitors Download PDFInfo
- Publication number
- AU2015263013B2 AU2015263013B2 AU2015263013A AU2015263013A AU2015263013B2 AU 2015263013 B2 AU2015263013 B2 AU 2015263013B2 AU 2015263013 A AU2015263013 A AU 2015263013A AU 2015263013 A AU2015263013 A AU 2015263013A AU 2015263013 B2 AU2015263013 B2 AU 2015263013B2
- Authority
- AU
- Australia
- Prior art keywords
- compound according
- compounds
- dimethyl
- triazolo
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)C(*=I)=*c1c(*)[n](*)c(C(C)(*)*)n1 Chemical compound CC(C)C(*=I)=*c1c(*)[n](*)c(C(C)(*)*)n1 0.000 description 3
- CJVXFXNWLNLYQU-UHFFFAOYSA-N Cc1cnc(C)c2nc(-c(nc3)cc4c3[nH]c(-c3ccccc3)n4)n[n]12 Chemical compound Cc1cnc(C)c2nc(-c(nc3)cc4c3[nH]c(-c3ccccc3)n4)n[n]12 CJVXFXNWLNLYQU-UHFFFAOYSA-N 0.000 description 1
- DXZMHHDREXGTKJ-UHFFFAOYSA-N Cc1cnc(C)c2nc(-c3cc(nc(-c4ccccc4)[nH]4)c4nc3)n[n]12 Chemical compound Cc1cnc(C)c2nc(-c3cc(nc(-c4ccccc4)[nH]4)c4nc3)n[n]12 DXZMHHDREXGTKJ-UHFFFAOYSA-N 0.000 description 1
- SDDSSZSKEQLSGW-UHFFFAOYSA-N OC(c(cc1)cc2c1[nH]c(-c1ccccc1)n2)=O Chemical compound OC(c(cc1)cc2c1[nH]c(-c1ccccc1)n2)=O SDDSSZSKEQLSGW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL408251A PL408251A1 (pl) | 2014-05-19 | 2014-05-19 | Skondensowane pochodne triazolu jako inhibitory fosfodiesterazy 10A |
| PLP.408251 | 2014-05-19 | ||
| PCT/IB2015/053549 WO2015177688A1 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10a inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015263013A1 AU2015263013A1 (en) | 2016-11-17 |
| AU2015263013B2 true AU2015263013B2 (en) | 2018-10-04 |
Family
ID=53434395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015263013A Active AU2015263013B2 (en) | 2014-05-19 | 2015-05-14 | Fused triazole derivatives as phosphodiesterase 10A inhibitors |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10138245B2 (enExample) |
| EP (1) | EP3145930B1 (enExample) |
| JP (1) | JP6455947B2 (enExample) |
| KR (1) | KR102404650B1 (enExample) |
| CN (1) | CN106459060B (enExample) |
| AU (1) | AU2015263013B2 (enExample) |
| CA (1) | CA2946258C (enExample) |
| DK (1) | DK3145930T3 (enExample) |
| EA (1) | EA030330B9 (enExample) |
| ES (1) | ES2688084T3 (enExample) |
| HR (1) | HRP20181027T1 (enExample) |
| HU (1) | HUE039847T2 (enExample) |
| MX (1) | MX367647B (enExample) |
| PL (2) | PL408251A1 (enExample) |
| PT (1) | PT3145930T (enExample) |
| SI (1) | SI3145930T1 (enExample) |
| WO (1) | WO2015177688A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017007301A1 (en) * | 2015-07-06 | 2017-01-12 | Universiti Sains Malaysia | Compound and method for inhibiting sirtuin activities |
| KR102587382B1 (ko) * | 2016-04-29 | 2023-10-12 | 솔루스첨단소재 주식회사 | 유기 발광 화합물 및 이를 이용한 유기 전계 발광 소자 |
| CN111410657B (zh) * | 2019-01-08 | 2024-05-21 | 北京鼎材科技有限公司 | 一种发光材料及其应用 |
| WO2025160629A1 (en) * | 2024-01-31 | 2025-08-07 | Certa Therapeutics Pty Ltd | Proton sensing gpcr modulators |
| US20250276984A1 (en) * | 2024-02-20 | 2025-09-04 | Iambic Therapeutics, Inc. | Solid state forms of her2 inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003298A2 (en) * | 2011-06-29 | 2013-01-03 | Bristol-Myers Squibb Company | Inhibitors of pde10 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2694983A1 (en) * | 2007-07-17 | 2009-01-22 | Combinatorx, Incorporated | Treatments of b-cell proliferative disorders |
| TWI501965B (zh) * | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| US8410117B2 (en) * | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
-
2014
- 2014-05-19 PL PL408251A patent/PL408251A1/pl unknown
-
2015
- 2015-05-14 EP EP15730261.3A patent/EP3145930B1/en active Active
- 2015-05-14 PT PT15730261T patent/PT3145930T/pt unknown
- 2015-05-14 CA CA2946258A patent/CA2946258C/en active Active
- 2015-05-14 ES ES15730261.3T patent/ES2688084T3/es active Active
- 2015-05-14 AU AU2015263013A patent/AU2015263013B2/en active Active
- 2015-05-14 EA EA201692264A patent/EA030330B9/ru not_active IP Right Cessation
- 2015-05-14 KR KR1020167035389A patent/KR102404650B1/ko active Active
- 2015-05-14 DK DK15730261.3T patent/DK3145930T3/en active
- 2015-05-14 CN CN201580025963.XA patent/CN106459060B/zh active Active
- 2015-05-14 US US15/311,698 patent/US10138245B2/en active Active
- 2015-05-14 HR HRP20181027TT patent/HRP20181027T1/hr unknown
- 2015-05-14 MX MX2016015180A patent/MX367647B/es active IP Right Grant
- 2015-05-14 JP JP2016568435A patent/JP6455947B2/ja active Active
- 2015-05-14 HU HUE15730261A patent/HUE039847T2/hu unknown
- 2015-05-14 SI SI201530382T patent/SI3145930T1/sl unknown
- 2015-05-14 WO PCT/IB2015/053549 patent/WO2015177688A1/en not_active Ceased
- 2015-05-14 PL PL15730261T patent/PL3145930T3/pl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013003298A2 (en) * | 2011-06-29 | 2013-01-03 | Bristol-Myers Squibb Company | Inhibitors of pde10 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946258C (en) | 2023-06-06 |
| MX367647B (es) | 2019-08-29 |
| EA030330B1 (ru) | 2018-07-31 |
| EP3145930B1 (en) | 2018-07-04 |
| JP2017521364A (ja) | 2017-08-03 |
| US10138245B2 (en) | 2018-11-27 |
| CA2946258A1 (en) | 2015-11-26 |
| PL3145930T3 (pl) | 2018-11-30 |
| US20170114064A1 (en) | 2017-04-27 |
| KR20170005860A (ko) | 2017-01-16 |
| DK3145930T3 (en) | 2018-09-24 |
| CN106459060A (zh) | 2017-02-22 |
| KR102404650B1 (ko) | 2022-06-02 |
| JP6455947B2 (ja) | 2019-01-23 |
| HUE039847T2 (hu) | 2019-02-28 |
| MX2016015180A (es) | 2017-03-23 |
| WO2015177688A1 (en) | 2015-11-26 |
| ES2688084T3 (es) | 2018-10-30 |
| PL408251A1 (pl) | 2015-11-23 |
| PT3145930T (pt) | 2018-10-11 |
| EA030330B9 (ru) | 2018-09-28 |
| HRP20181027T1 (hr) | 2018-08-24 |
| AU2015263013A1 (en) | 2016-11-17 |
| CN106459060B (zh) | 2019-04-05 |
| EA201692264A1 (ru) | 2017-04-28 |
| EP3145930A1 (en) | 2017-03-29 |
| SI3145930T1 (sl) | 2018-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015263013B2 (en) | Fused triazole derivatives as phosphodiesterase 10A inhibitors | |
| US8975276B2 (en) | Inhibitors of PDE10 | |
| TWI481607B (zh) | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 | |
| EP2434885B1 (en) | Alkoxy tetrahydro-pyridopyrimidine pde10 inhibitors | |
| CA2779303A1 (en) | Bicyclic pyridines and analogs as sirtuin modulators | |
| CA2723237A1 (en) | Substituted amides, method of making, and use as btk inhibitors | |
| MX2009001451A (es) | Derivado de pirimidina como inhibidor de pi3k y uso del mismo. | |
| AU2005289644A1 (en) | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | |
| JP2009531274A (ja) | キナーゼ阻害性ピロロピリジン化合物 | |
| NO167979B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazopyridiner | |
| WO2017003894A1 (en) | Substituted triazolo bicyclic compounds as pde2 inhibitors | |
| CA3219925A1 (en) | Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of cancer | |
| KR19980064040A (ko) | 피리딘 유도체, 피리딘 유도체의 제조 방법 및 그를 위한 중간체 | |
| US10647727B2 (en) | Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitors | |
| US20240368188A1 (en) | Positive allosteric modulators of the muscarinic acetylcholine receptor m4 | |
| PH12014501434B1 (en) | Quinoline derivatives as pde10a enzyme inhibitors | |
| KR20250174938A (ko) | 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 티아졸로피리딘 유도체 | |
| BR112016027023B1 (pt) | Derivados de triazol fundidos como inibidores de fosfodiesterase 10a | |
| AU2023380028A1 (en) | Pyridone and pyrimidinone inhibitors of hematopoietic progenitor kinase 1 | |
| NZ626279B2 (en) | Quinoline derivatives as pde10a enzyme inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |